Irreversible Electroporation Margin Accentuation in Pancreaticoduodenectomy: A Propensity Score Matching Analysis
- Joseph S Lim 1, Jessica Heard 1,2, Nick Brant 2,3, Juan Malo 1, Joshua Kong 1, Houssam Osman 4, Joseph Buell 1,4, Dhiresh Rohan Jeyarajah 5,6
- Joseph S Lim 1, Jessica Heard 1,2, Nick Brant 2,3
- 1Department of Surgery, Methodist Health System, Dallas, TX, USA.
- 2Department of Surgery, University of Oklahoma School of Medicine, Tulsa, OK, USA.
- 3Department of Surgery, Emory University, Atlanta, GA, USA.
- 4Department of Surgery, Anne Burnett School of Medicine at, Texas Christian University, Fort Worth, TX, USA.
- 5Department of Surgery, Methodist Health System, Dallas, TX, USA. drj@tscsurgical.com.
- 6Department of Surgery, Anne Burnett School of Medicine at, Texas Christian University, Fort Worth, TX, USA. drj@tscsurgical.com.
- 0Department of Surgery, Methodist Health System, Dallas, TX, USA.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Margin accentuation using irreversible electroporation (MA-IRE) improves overall survival in pancreatic cancer patients. This technique is safe and may activate immune cells, but does not affect recurrence or complications.
Area Of Science
- Oncology
- Surgical Oncology
- Medical Technology
Background
- Pancreatic cancer presents significant challenges in treatment and survival.
- Margin accentuation using irreversible electroporation (MA-IRE) is a technique explored to improve outcomes.
- Limited comparative data exists for MA-IRE versus standard care in pancreatic cancer patients.
Purpose Of The Study
- To compare outcomes of pancreatic cancer patients treated with MA-IRE versus those who did not receive MA-IRE.
- To evaluate the impact of MA-IRE on overall survival (OS), disease-free survival (DFS), margin status, and complications.
- To assess the safety and potential mechanisms of MA-IRE in pancreaticoduodenectomy (PD).
Main Methods
- Retrospective analysis of pancreatic adenocarcinoma patients undergoing PD (2017-2022).
- Exclusion of patients who received neoadjuvant chemotherapy for major vessel involvement.
- One-to-one propensity score matching (PSM) to create comparable MA-IRE and non-MA-IRE groups.
Main Results
- Seventeen MA-IRE patients were matched with 19 non-MA-IRE controls.
- MA-IRE group demonstrated significantly improved OS (746 vs. 509 days, p=0.034).
- No significant differences were observed in DFS, margin status, or 30-day complication rates between groups post-matching.
Conclusions
- MA-IRE in PD is associated with longer OS in pancreatic cancer patients.
- MA-IRE does not appear to impact margin status, DFS, or postoperative complications.
- Findings suggest MA-IRE may promote immune activation rather than direct margin control.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

